Alzamend Neuro Statistics
Total Valuation
Alzamend Neuro has a market cap or net worth of $6.31 million. The enterprise value is $3.64 million.
Important Dates
The last earnings date was Monday, March 10, 2025, after market close.
Earnings Date | Mar 10, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Alzamend Neuro has 6.60 million shares outstanding. The number of shares has increased by 294.83% in one year.
Current Share Class | 6.60M |
Shares Outstanding | 6.60M |
Shares Change (YoY) | +294.83% |
Shares Change (QoQ) | +56.24% |
Owned by Insiders (%) | 0.83% |
Owned by Institutions (%) | 3.18% |
Float | 6.44M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.78 |
P/TBV Ratio | 2.03 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.44
Current Ratio | 5.44 |
Quick Ratio | 4.63 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -221.65 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -106.08% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -121.98% |
Revenue Per Employee | n/a |
Profits Per Employee | -$603,848 |
Employee Count | 7 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.61% in the last 52 weeks. The beta is -0.30, so Alzamend Neuro's price volatility has been lower than the market average.
Beta (5Y) | -0.30 |
52-Week Price Change | -89.61% |
50-Day Moving Average | 0.99 |
200-Day Moving Average | 1.97 |
Relative Strength Index (RSI) | 62.60 |
Average Volume (20 Days) | 208,111 |
Short Selling Information
The latest short interest is 120,915, so 1.83% of the outstanding shares have been sold short.
Short Interest | 120,915 |
Short Previous Month | 228,201 |
Short % of Shares Out | 1.83% |
Short % of Float | 1.88% |
Short Ratio (days to cover) | 0.14 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -4.21M |
Pretax Income | -9.95M |
Net Income | -4.23M |
EBITDA | -4.16M |
EBIT | -4.21M |
Earnings Per Share (EPS) | -$1.61 |
Full Income Statement Balance Sheet
The company has $3.36 million in cash and n/a in debt, giving a net cash position of $3.36 million or $0.51 per share.
Cash & Cash Equivalents | 3.36M |
Total Debt | n/a |
Net Cash | 3.36M |
Net Cash Per Share | $0.51 |
Equity (Book Value) | 3.45M |
Book Value Per Share | 0.60 |
Working Capital | 3.22M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$7.31 million and capital expenditures -$90,000, giving a free cash flow of -$7.40 million.
Operating Cash Flow | -7.31M |
Capital Expenditures | -90,000 |
Free Cash Flow | -7.40M |
FCF Per Share | -$1.12 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -294.83% |
Shareholder Yield | n/a |
Earnings Yield | -60.44% |
FCF Yield | -105.76% |
Analyst Forecast
The average price target for Alzamend Neuro is $20.00, which is 1,990.08% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $20.00 |
Price Target Difference | 1,990.08% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | 27.15% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on July 16, 2024. It was a reverse split with a ratio of 0.1:1.
Last Split Date | Jul 16, 2024 |
Split Type | Reverse |
Split Ratio | 0.1:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |